Alexander Bolaender

Eli Lilly (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

17h-index1.2kcitations48works0.92yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Heat shock proteins research(19), Glutathione Transferases and Polymorphisms(15), Advanced biosensing and bioanalysis techniques(9), Ubiquitin and proteasome pathways(7), Biosensors and Analytical Detection(6)

Publications48 total

Radiolabeling of Flutemetamol F18 and Analogue Using Dibenzothiophenium Salts Precursor
Nuclear Medicine and Biology·2025Open Access
ImmunoPET for mesothelin positive tissues using bio-orthogonal in-vivo click chemistry
Nuclear Medicine and Biology·2025· 1 citedOpen Access
Supplementary Table S2 from Pretargeted Trop-2 ImmunoPET for Rapid, Selective Detection of Pancreatic Tumors
2025Open Access
Supplementary Figure S1 from Pretargeted Trop-2 ImmunoPET for Rapid, Selective Detection of Pancreatic Tumors
2025Open Access
Supplementary Figure S2 from Pretargeted Trop-2 ImmunoPET for Rapid, Selective Detection of Pancreatic Tumors
2025Open Access
Supplementary Figure S4 from Pretargeted Trop-2 ImmunoPET for Rapid, Selective Detection of Pancreatic Tumors
2025Open Access
Supplementary Figure S3 from Pretargeted Trop-2 ImmunoPET for Rapid, Selective Detection of Pancreatic Tumors
2025Open Access
Supplementary Table S1 from Pretargeted Trop-2 ImmunoPET for Rapid, Selective Detection of Pancreatic Tumors
2025Open Access
Data from Pretargeted Trop-2 ImmunoPET for Rapid, Selective Detection of Pancreatic Tumors
2025Open Access
Pretargeted Trop-2 ImmunoPET for Rapid, Selective Detection of Pancreatic Tumors
Clinical Cancer Research·2025· 8 citedOpen Access
Supplemental Figure 5 from Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma
2023Open Access
Supplemental Figure 3 from Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma
2023Open Access
Supplemental Figure 3 from Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma
2023Open Access
Supplemental Table 2 from Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma
2023Open Access
Supplemental Figure Legends from Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma
2023Open Access
Supplemental Figure 1 from Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma
2023Open Access
Supplemental Figure 6 from Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma
2023Open Access
Supplemental Figure 4 from Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma
2023Open Access
Supplemental Figure 4 from Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma
2023Open Access
Supplemental Figure 2 from Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Gabriela Chiosis(34), Tony Taldone(32), Hediye Erdjument‐Bromage(24), Ethel Cesarman(22), Lisa Giulino‐Roth(21), Herman J. van Besien(21), Tanner C. Dalton(21), Jennifer Totonchy(21), Jouliana Sadek(21), Amy Chadburn(21), Filemon S. Dela Cruz(21), Allison R. Rainey(21), Andrew L. Kung(21), A. V. Rodina(20), Jason S. Lewis(14), Matthew Barth(12), Nagavarakishore Pillarsetty(9), Matthew J. Barth(9), Edwin C. Pratt(9), Komal Mandleywala(9)